Deoxycytidine Kinase (dCK) has been implicated in cancer cell proliferation. Our dCK inhibitor, TRE-515, has been chemically engineered to improve bioavailability and demonstrates robust anti-tumor activity in combination therapies.
TRE-515, a First-in-Class inhibitor for leukemia
TRE-515 is deoxycytidine kinase (dCK) inhibitor with nanomolar affinity and is being developed as a dual therapy for the treatment of acute leukemia (ALL, AML, and chronic leukemia in an accelerated phase or blast crisis). dCK is the rate-limiting enzyme in the salvage pathway of nucleotide synthesis.
TRE-515 will qualify as an Orphan Indication in both the US and Europe, and, following regulatory approval, “data exclusivity” will apply in the US for five years and in Europe for 11 years.
A dual attack on cancer
Triapine® is a clinical-stage, potent inhibitor of ribonucleotide reductase (RNR). RNR is the key enzyme in the de novo pathway of nucleotide synthesis, and RNR activity has been implicated in disease progression and treatment resistance in several cancers.
Through dissection of the nucleotide biosynthesis pathways in tumors, Trethera has devised a new and precise combination therapy that selectively targets pathways that lead to progression and drug resistance. With the combination therapy of TRE-515 and Triapine®, the company aims to demonstrate the clinical efficacy of a dual blockade of these nucleotide synthesis pathways.